Bristol-Myers Squibb Ends Partnership with Cellares, Raising Concerns About Breyanzi Manufacturing
Bristol-Myers Squibb (NYSE:BMY) has terminated its partnership with cell therapy manufacturer Cellares after determining that the latter's Cell Shuttle platform could not meet commercial-scale manufacturing requirements for Breyanzi. The $380 million collaboration, announced in 2024, aimed to expand production of the CAR-T drug across key markets including the U.S., Europe, and Japan. Breyanzi is a critical revenue driver for BMY, generating $1.36 billion in sales in 2025. The partnership's dissolution has raised concerns about the company’s ability to scale its cell therapy manufacturing efficiently as demand grows. However, BMY emphasized that the decision relates specifically to Cellares' platform and not to Breyanzi itself or broader CAR-T development. While some analysts view this move as a disciplined step toward ensuring product quality and supply reliability, others highlight potential challenges in scaling up production of complex cell therapies like Breyanzi. The termination also underscores ongoing difficulties within the industry regarding manufacturing scalability.
Tickers: $BMY